Derik De Bruin

Derik De Bruin Recent News

8 2019 IPO Stocks To Buy, Sell Or Hold
BofA Double Downgrades Illumina After Thursday's 'Big Miss'
Bank Of America Upgrades Guardant Health On Huge Growth Potential
Hologic Downgraded By BofA As Cynosure Headwinds Persist
BofA Upgrades Iqvia On Upside Potential
In Its Best Year Since Going Public, Q4 A Catalyst For Catalent
IDEXX Labs Is 'Top Dog'
UPDATE: Bank Of America Reiterates On Mettler-Toledo International On Takeaways From Investor Meeting
UPDATE: Bank Of America Reiterates On Catalent On Operationally Solid F1Q
UPDATE: Bank Of America Reiterates On Agilent Technologies Following Investor Presentations
UPDATE: Bank Of America Reiterates On FEI Company On Solid Q2/Weak 2H14 Guidance
UPDATE: Bank of America Reiterates On Affymetrix As Growth/Profitability Improve
UPDATE: Bank of America Reiterates on Thermo Fisher Scientific on Favorable Risk-Reward
UPDATE: Bank Of America Reiterates On Quintiles Transnational Holdings On Strong Product Development Sales
UPDATE: Bank of America Reiterates on Genomic Health as 2014 Outlook is Below Expectations
Bank of America Comments on FDA Approval of Bruker Corporation's MALDI Biotyper CA System
UPDATE: Bank of America Downgrades Waters Corporation Following Weaker 3Q13 Earnings Results
UPDATE: Bank of America Downgrades Cepheid on Fair Valuation
UPDATE: Bank of America Downgrades Genomic Health on Lack of Near-Term Catalysts, Limited Upside
UPDATE: Bank of America Upgrades Bruker on Margin Potential
UPDATE: Bank of America Initiates Quintiles Transnational at Buy on Positive Outlook
UPDATE: Bank of America Downgrades Genomic Health on Lack of Catalysts
UPDATE: Bank of America Downgrades Myriad Genetics as Competitive Concerns Emerge

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved